We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+24.54%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$278M
AUM Growth
+$61.2M
Cap. Flow
+$17.6M
Cap. Flow %
6.32%
Top 10 Hldgs %
51.21%
Holding
67
New
9
Increased
19
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$11.7M
2
MRK icon
Merck
MRK
+$7.14M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$5.27M
4
HALO icon
Halozyme
HALO
+$4.42M
5
BIIB icon
Biogen
BIIB
+$3.88M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$17M
2
INSM icon
Insmed
INSM
+$6.57M
3
PTCT icon
PTC Therapeutics
PTCT
+$5.18M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.7M
5
INCY icon
Incyte
INCY
+$2.78M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IFRX icon
51
InflaRx
IFRX
$335M
$869K 0.31%
+220,000
New +$643K
KYNB
52
Kyntra Bio
KYNB
$32.4M
$845K 0.3%
788
– –
INSM icon
53
Insmed
INSM
$26.5B
$801K 0.29%
33,600
-323,000
-91% -$6.57M
ARNA
54
DELISTED
Arena Pharmaceuticals Inc
ARNA
$749K 0.27%
16,500
– –
MYGN icon
55
Myriad Genetics
MYGN
$304M
$680K 0.25%
25,000
– –
AKCA
56
DELISTED
Akcea Therapeutics Inc
AKCA
$536K 0.19%
31,723
– –
SUPN icon
57
Supernus Pharmaceuticals
SUPN
$2.57B
$473K 0.17%
19,953
– –
DERM
58
DELISTED
Dermira, Inc.
DERM
$454K 0.16%
30,000
– –
MOR
59
DELISTED
MorphoSys AG American Depositary Shares
MOR
$402K 0.14%
+11,295
New +$337K
RDUS
60
DELISTED
Radius Health, Inc.
RDUS
$342K 0.12%
17,000
– –
GTHX
61
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$296K 0.11%
11,200
– –
ZEAL
62
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$188K 0.07%
+5,653
New +$169K
ANAB icon
63
AnaptysBio
ANAB
$1.7B
$163K 0.06%
10,000
– –
RGEN icon
64
Repligen
RGEN
$10.3B
– –
-24,000
Closed -$1.84M
ABMD
65
DELISTED
Abiomed Inc
ABMD
– –
-11,700
Closed -$2.08M
ARQL
66
DELISTED
Arqule Inc
ARQL
– –
-41,000
Closed -$294K
CELG
67
DELISTED
Celgene Corp
CELG
– –
-171,022
Closed -$17M
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2019 Portfolio in Review

As of Q4 2019, International Biotechnology Trust held 67 positions worth $278M, up 28% from $216M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

International Biotechnology Trust deployed $17.6M of net new capital in Q4 2019, opening 9 new positions and adding to 19 existing holdings. Its largest new stake was Merck: 86,984 shares worth $7.55M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $6.57M trimmed.

  • International Biotechnology Trust's largest Q4 2019 buy was Merck: 86,984 shares worth $7.55M.
  • International Biotechnology Trust added most to Acadia Pharmaceuticals in Q4 2019, an estimated $11.7M increase.
  • International Biotechnology Trust's biggest Q4 2019 reduction was Insmed, cutting an estimated $6.57M.
  • International Biotechnology Trust fully exited Celgene Corp in Q4 2019, selling an estimated $17M.
  • International Biotechnology Trust's ten largest holdings make up 51% of its $278M portfolio in Q4 2019.
  • International Biotechnology Trust opened 9 new positions and closed 4 in Q4 2019.
  • International Biotechnology Trust's portfolio value rose 28% quarter-over-quarter to $278M.

Based on International Biotechnology Trust's 13F filing for Q4 2019, filed 18 May 2020.